SubsidieMeestersTransformational crossing system to prevent amputation and treat complex chronic total occlusions in critical limb ischemia
Versono's CTO guidewire uses ultrasound to enable endovascular surgeons to effectively treat 90% of chronic total occlusions, aiming to restore blood flow and prevent limb amputation in CLTI patients.
Projectdetails
Introduction
Critical limb threatening ischemia (CLTI) is caused by chronic total occlusions (CTOs) in the arteries of the lower extremities. Left untreated, the complications of CLTI result in amputation of the affected limb. The prognosis for those diagnosed with CLTI is comparable to that of an aggressive cancer.
Prognosis
At 1 year post diagnosis:
- 25% of patients will die
- 30% have had an amputation
- 60% are dead by year 5
Cause of CTO
CTO is caused by the build-up and calcification of plaque inside the artery, which blocks the artery. This condition hardens over time and prevents the passage of a guidewire or therapy device through the vessel.
Versono's Solution
Versono has designed and developed a solution to allow an endovascular surgeon to confidently cross 90% of occlusions within 10 minutes.
Technology Overview
This dedicated CTO guidewire uses an acoustic wave (ultrasound) to penetrate through the calcium/plaque. This enables physicians to apply other treatments such as:
- Stents
- Balloons
- Atherectomy devices
These treatments help to unblock the CTO and restore blood flow to the tissue downstream.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.478.175 |
| Totale projectbegroting | € 3.544.625 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- VERSONO MEDICAL LIMITEDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
THE NEXT STENT GENERATION: A FIRST-IN-CLASS REGENERATIVE NANOFIBER STENT TO RECONSTRUCT ARTERIES FROM THE INSIDE OUTSTENTiT aims to revolutionize BTK-CLI treatment with a regenerative stent that promotes vascular restoration and reduces complications, seeking €2.5M in grants and €10M in equity for clinical studies. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Diagnosis of large vessel occlusion (LVO) in acute stroke for improving access to treatmentLVOCheck is a portable diagnostic tool that rapidly identifies large vessel occlusion in stroke patients using a blood drop, enabling faster treatment and improving patient outcomes. | EIC Accelerator | € 2.772.276 | 2023 | Details |
Life Saving Technology for Thoracic Trauma Treatment and Post Operative DrainageC-LANT is an innovative, multifunctional device designed to rapidly and effectively treat thoracic trauma, aiming to significantly reduce procedure time and healthcare costs while improving patient outcomes. | EIC Accelerator | € 2.499.875 | 2023 | Details |
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market. | EIC Accelerator | € 2.498.816 | 2024 | Details |
THE NEXT STENT GENERATION: A FIRST-IN-CLASS REGENERATIVE NANOFIBER STENT TO RECONSTRUCT ARTERIES FROM THE INSIDE OUT
STENTiT aims to revolutionize BTK-CLI treatment with a regenerative stent that promotes vascular restoration and reduces complications, seeking €2.5M in grants and €10M in equity for clinical studies.
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
Diagnosis of large vessel occlusion (LVO) in acute stroke for improving access to treatment
LVOCheck is a portable diagnostic tool that rapidly identifies large vessel occlusion in stroke patients using a blood drop, enabling faster treatment and improving patient outcomes.
Life Saving Technology for Thoracic Trauma Treatment and Post Operative Drainage
C-LANT is an innovative, multifunctional device designed to rapidly and effectively treat thoracic trauma, aiming to significantly reduce procedure time and healthcare costs while improving patient outcomes.
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
VR claudicatio therapieHet project ontwikkelt een VR-applicatie om patiënten met claudicatio te ondersteunen tijdens looptherapie, met als doel de effectiviteit van de behandeling en de kwaliteit van leven te verbeteren. | Mkb-innovati... | € 160.690 | 2019 | Details |
MicroHeartHet project ontwikkelt een gestandaardiseerd productieproces voor de ELANA Heart Bypass, een minimaal-invasieve behandeling voor coronaire hartziekten, ter verbetering van patiëntenzorg en commercialisatie. | Mkb-innovati... | € 155.525 | 2018 | Details |
Occlufibre haalbaarheidOcclufibre onderzoekt de ontwikkeling van een op maat gemaakte embolisatie fibre voor veiligere en snellere interventies bij vaatafwijkingen. | Mkb-innovati... | € 20.000 | 2024 | Details |
NanoStentDit project ontwikkelt een volledig opneembare stent voor de behandeling van kritische ischemie, ter vermindering van amputaties en zorgkosten. | Mkb-innovati... | € 350.000 | 2022 | Details |
Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosisThis project aims to investigate the impact of DNMT3A mutations on aortic valve stenosis progression and cardiac fibrosis, seeking biomarkers and therapeutic targets for high-risk patients. | ERC Advanced... | € 2.225.906 | 2022 | Details |
VR claudicatio therapie
Het project ontwikkelt een VR-applicatie om patiënten met claudicatio te ondersteunen tijdens looptherapie, met als doel de effectiviteit van de behandeling en de kwaliteit van leven te verbeteren.
MicroHeart
Het project ontwikkelt een gestandaardiseerd productieproces voor de ELANA Heart Bypass, een minimaal-invasieve behandeling voor coronaire hartziekten, ter verbetering van patiëntenzorg en commercialisatie.
Occlufibre haalbaarheid
Occlufibre onderzoekt de ontwikkeling van een op maat gemaakte embolisatie fibre voor veiligere en snellere interventies bij vaatafwijkingen.
NanoStent
Dit project ontwikkelt een volledig opneembare stent voor de behandeling van kritische ischemie, ter vermindering van amputaties en zorgkosten.
Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosis
This project aims to investigate the impact of DNMT3A mutations on aortic valve stenosis progression and cardiac fibrosis, seeking biomarkers and therapeutic targets for high-risk patients.